(vii) The ASOs should have low toxicity, immunogenicity, mutagenicity, and should have a large therapeutic window. (vi) The cost of production should be low. (v) The ASOs should not non-specifically interact with other cellular factors. (iv) The ASOs must effectively interact with the target. (iii) The ASOs must be retained by the cells. (ii) The ASOs must be efficiently taken up by the cells. (i) The ASOs must be stable to degradation in vivo. The high association constants imply a strong duplex formation and thus effectiveness at low concentrations.įor ASO therapy, several criteria are important. These advantages include the extremely high specificity and the ease of design afforded by Watson-Crick base pairing. Oligonucleotides for therapy have several advantages. Other regulatory mechanisms of viruses, such as HIV, are also open to interference with the use of complimentary (i.e. Production of viral proteins can be inhibited by oligonucleotides that are complimentary to portions of mRNA for that protein (i.e. This regulatory interference can be harnessed for therapeutic effects against many diseases and viral infections. "decoy") oligonucleotides, oligoribonucleotides, and modified oligonucleotides (collectively referred to herein as ASOs) are gaining overwhelming popularity for interference in various steps leading from DNA transcription to mRNA translation. sequences complementary to the "sense" strand, usually the messenger RNA) and otherwise interfering (e.g. C07H21/00- Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g.C07H- SUGARS DERIVATIVES THEREOF NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS.Anticipated expiration legal-status Critical Status Expired - Lifetime legal-status Critical Current Links ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Application granted granted Critical Publication of US6015886A publication Critical patent/US6015886A/en Assigned to LAKEWOOD-AMEDEX, INC. Assignors: ARROW, AMY, DALE, RODERIC M.K. Assignors: RAZA, SYED K., SRIVASTAVA, SURESH C. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US66244796A external-priority Priority claimed from US08/065,016 external-priority patent/US5525719A/en Application filed by ChemGenes Corp, Oligos Etc Inc filed Critical ChemGenes Corp Priority to US08/795,926 priority Critical patent/US6015886A/en Assigned to CHEMGENES CORPORATION reassignment CHEMGENES CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Original Assignee ChemGenes Corp Oligos Etc Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Raza Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Expired - Lifetime Application number US08/795,926 Inventor Roderic M.
SUGAR PHOSPHATE BACKBONE ESTER PDF
Google Patents Oligonucleotide phosphate estersĭownload PDF Info Publication number US6015886A US6015886A US08/795,926 US79592697A US6015886A US 6015886 A US6015886 A US 6015886A US 79592697 A US79592697 A US 79592697A US 6015886 A US6015886 A US 6015886A Authority US United States Prior art keywords group alkyl methyl propyl ethyl Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US6015886A - Oligonucleotide phosphate esters US6015886A - Oligonucleotide phosphate esters
0 kommentar(er)
